| 产品描述: | PF-670462是有效的、选择性CK1ε和CK1δ抑制剂,IC50分别为90 nM和13 nM |
| 靶点: |
CK1δ(Cell-free assay):13 nM; CK1ε(Cell-free assay):90 nM;CaseinKinase |
| 体外研究: |
PF-670462 is a 14 nM inhibitor of CK1δ in vitro and also potently inhibits p38 and EGFR[1]. In vitro, PF670462 prevents TGF-β-induced epithelial-mesenchymal transition |
| 体内研究: |
PF670462 administered systemically or locally by inhalation prevents both acute and chronic bleomycin-induced pulmonary fibrosis in mice |
| 细胞实验: |
Cell lines: A549 cells Concentrations: 0.3-10 μM Incubation Time: 48 h Method: A549 cells are left to adhere overnight. Cells are then serum-starved for 16 h prior to pre-incubation with PF670462 (0.3-10 μM) for 30 min then TGF-β (100 pM) for 48 h. Cells are fixed in 10% neutral buffered formalin for 15 min and non-specific binding sites are blocked by incubation with 5% normal goat serum/0.3% Triton X-100 in PBS for 1 h. E-Cadherin expression is detected by immunofluorescence staining. |
| 动物实验: |
Animal Models: Six- to eight-week old 20–25 g C57Bl/6 mice Dosages: 30 mg/kg/day Administration: IP |
| 参考文献: |
1. Mathieu Bibian, et al. Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett. 2013, 23(15): 4374–4380. 2. Keenan CR, et al. Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis. Front Pharmacol. 2018, 9:738. |
| 溶解性: |
Soluble in DMSO、H2O、Ethanol |
| 保存条件: |
2-8℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.437 ml |
12.186 ml |
24.371 ml |
| 5 mM |
0.487 ml |
2.437 ml |
4.874 ml |
| 10 mM |
0.244 ml |
1.219 ml |
2.437 ml |
| 50 mM |
0.049 ml |
0.244 ml |
0.487 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |